Donanemab slowed cognitive and functional decline of patients with mild Alzheimer’s by 32% compared with placebo<p>Link to press release: <a href="https://www.prnewswire.com/news-releases/lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial-301204830.html" rel="nofollow">https://www.prnewswire.com/news-releases/lillys-donanemab-sl...</a>